Assessing CRISPR Therapeutics Stock After 24.6% Drop and Breakthrough Gene Editing News

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about this innovative biotech company. It has been a wild ride for shareholders lately, with the stock down 13.9% over the last week and 24.6% over the last month, but it is still up an impressive 33.0% year to date. Recent media coverage has focused on CRISPR Therapeutics' groundbreaking gene-editing advancements, regulatory milestones, and partnerships in the biotech space. All of these factors have increased investor attention. These developments help explain both the volatility and the strong underlying interest from the market. When it comes to valuation, CRISPR Therapeutics scores a 3 out of 6 on our value checks. There is more to explore regarding how analysts and investors view the company's worth, and later on, we will share an even more effective way to think about its true value.

CRISPR Therapeutics delivered 6.8% returns over the last year. See how this stacks up to the rest of the Biotechs industry.

Approach 1: CRISPR Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow (DCF) model estimates a company’s value by projecting its future cash flows and then discounting those projections back to today’s value. This method is popular for fast-growing or innovative companies like CRISPR Therapeutics, as it aims to account for both near-term challenges and long-term growth potential.

According to the data, CRISPR Therapeutics currently reports a free cash flow of -$329.5 million. Analysts expect these figures to turn positive in coming years, with free cash flow projected to reach $136.5 million by the end of 2029. For the longer term, projections out to 2035 show a strong acceleration in free cash flow, as modeled by Simply Wall St. It is worth noting that analyst estimates cover approximately five years. Years further out are based on extrapolations and estimates beyond current analyst consensus.

Based on the 2 Stage Free Cash Flow to Equity model, the estimated fair value per share is $130.38. This suggests that the stock is trading at a 57.7% discount compared to this intrinsic value and may be considered significantly undervalued at the current market price.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CRISPR Therapeutics is undervalued by 57.7%. Track this in your watchlist or portfolio, or discover 877 more undervalued stocks based on cash flows.CRSP Discounted Cash Flow as at Nov 2025

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CRISPR Therapeutics.

Story Continues

Approach 2: CRISPR Therapeutics Price vs Book

For companies that are either not yet profitable or where tangible assets play a key role, the Price-to-Book (PB) ratio is a useful valuation metric. It tells us how much investors are paying for each dollar of the company’s net assets, which is particularly relevant for biotech firms like CRISPR Therapeutics that are still ramping up commercial operations and may be valued more for their research pipeline than for current profits.

Looking at the numbers, CRISPR Therapeutics currently trades at a PB ratio of 2.93x. This is higher than the biotech industry average of 2.44x, but it is notably lower than the average for its closest peers, which is around 6.18x. On the face of it, the company's shares do not appear overly expensive based on this multiple, especially compared with similar companies in the sector.

Simply Wall St’s proprietary "Fair Ratio" aims to go a step further than simple peer or industry comparisons. It calculates a company’s fair valuation multiple by weighing in factors such as expected earnings growth, risk profile, profit margins, market capitalization, and the specific characteristics of the biotech industry. This makes it a more nuanced and forward-looking tool for investors.

By comparing the Fair Ratio to CRISPR Therapeutics' current PB multiple, we can get a more accurate sense of value. In this case, because the Fair Ratio and the actual PB ratio are nearly identical, the stock’s value is considered to be about right at current levels.

Result: ABOUT RIGHTNasdaqGM:CRSP PB Ratio as at Nov 2025

PB ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1404 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your CRISPR Therapeutics Narrative

Earlier we mentioned that there's an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is a simple, powerful tool that allows you to tell your unique story behind the numbers. It reflects your view of a company’s fair value through your own assumptions about future revenue, profit margins, and the big picture. Narratives connect the dots by linking CRISPR Therapeutics’ business story to a financial forecast and ultimately to a fair value estimate, helping you make smart buy or sell decisions by comparing the Fair Value to today's stock price.

This feature is easy to use and fully accessible right on Simply Wall St’s Community page, where millions of investors share and compare their Narratives. As new information such as company news or earnings emerges, Narratives dynamically update, keeping your analysis current. For example, one user might project a highly optimistic scenario with breakthrough approvals, while another sees a slower growth path and a more conservative valuation. Both perspectives are brought to life with numbers. Narratives offer a smarter, more flexible way to evaluate opportunities and risks, making investment decision-making not only more insightful but also truly personal.

Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying!NasdaqGM:CRSP Community Fair Values as at Nov 2025

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include CRSP.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments